Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma

Inclusion Criteria:

- Patient must have a confirmed diagnosis of multiple myeloma. The patient may be any
stage of multiple myeloma. The patient may have received one or more lines of prior
therapy (there is no limit to number of prior lines of therapy permissible).

- Patient must be ≥18 years of age

- Patient must be in active treatment with one of the following:

- twice-weekly bortezomib (on Days 1, 4, 8, and 11 of a 21-day cycle) with or
without dexamethasone

- carfilzomib (on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle) with or without
dexamethasone

- an IMID with or without dexamethasone daily on Days 1 to 21.

- Patients being treated with bortezomib or carfilzomb may also be receiving an
IMID or PO cyclophosphamide with the regimen.

- Patient must have shown stable or progressive disease on the current bortezomib-,
carfilzomib-, or IMID-containing regimen with a measurable monoclonal protein
component in the serum (at least 0.5 g/dl on electrophoresis or 0.05 g/dl [50mg/dl]
on serum-free-light-chain). Patients who had an initial response on the current
bortezomib-, carfilzomib-, or IMID-containing regimen but now have stable (plateaued)
disease are eligible.

- Patient must have an ECOG performance status of 0 - 2

- Patient must be receiving concurrent treatment with bisphosphonates, with one dose
occurring within 30 days prior to first day (Day -3) of protocol treatment

- Patient must have acceptable hematologic parameters, defined as:

- Absolute neutrophil count > 1000 cells/mm3

- Platelets ≥ 50,000 cells/mm3

- Hemoglobin ≥ 8 g/dl

- Patient must have adequate liver function, defined as:

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 x upper
limit of normal

- Total bilirubin < 2 x upper limit of normal

- Patient must be able to understand and willing to sign a written informed consent
document

Exclusion Criteria:

- Patient must not be receiving any agents with known or suspected anti-myeloma
activity (other than bortezomib, carfilzomib, dexamethasone, an IMID or PO
cyclophosphamide, and bisphosphonates with the current regimen)

- Patient must not be actively using myeloid growth factors

- Patient must not have had any prior malignancy, except for adequately treated basal
cell or squamous cell skin cancer, in-situ cervical cancer, or other cancer from
which the subject has been disease-free for at least 2 years

- Patient must not have any uncontrolled medical problems such as diabetes mellitus,
coronary artery disease, hypertension, unstable angina, arrhythmias, pulmonary
disease, and symptomatic heart failure

- Patient must not have neuropathy ≥ grade 3 or painful neuropathy ≥ grade 2 (NCI CTCAE
v 4.0)

- Patient must not have any known active infections requiring IV antibiotic, antiviral,
or antifungal therapy

- Patient must not be pregnant or breastfeeding